title: Pulse cyclophosphamide therapy in the management of patients with macular serpiginous choroidopathy.
abstract: OBJECTIVE
  To evaluate safety and efficacy of intravenous pulse cyclophosphamide (CyP) in acute macular serpiginous choroiditis (SC).
  
  
  METHODS
  Patients with acute macular SC with lesions threatening and/or involving fovea were enrolled. All patients received CyP (1 g/m2) for 3 days followed by high-dose oral steroids (1.5 mg/kg) tapered over 6 months and monitored for visual acuity, response to treatment and systemic side effects.
  
  
  RESULTS
  Eight patients (seven unilateral and one bilateral) with median age of 27 years (range: 13-40 years) were recruited. Mean visual acuity at presentation was 0.71 ± 0.35 logarithm of the minimum angle of resolution while postpulse visual acuity was 0.40 ± 0.32. Final mean visual acuity at 1-year was 0.31 ± 0.23 (P ≤ 0.05). Three eyes had recurrence and 3 patients developed transient hair loss with no other adverse effect.
  
  
  CONCLUSIONS
  Intravenous CyP provides rapid resolution of lesion activity and thereby helps in maintaining good functional acuity.
authors.forename: Pradeep
authors.initials: P
authors.lastname: Venkatesh
authors.affiliation: Department of Ophthalmology, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Varun
authors.initials: V
authors.lastname: Gogia
authors.forename: Shikha
authors.initials: S
authors.lastname: Gupta
authors.forename: Akshay
authors.initials: A
authors.lastname: Tayade
authors.forename: Neha
authors.initials: N
authors.lastname: Shilpy
authors.forename: Bhavin M
authors.initials: BM
authors.lastname: Shah
authors.forename: Randeep
authors.initials: R
authors.lastname: Guleria
mesh_terms: D000293:Adolescent; D000328:Adult; D002833:Choroiditis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007262:Infusions, Intravenous; D008266:Macula Lutea / Q000473:pathology*; D008297:Male; D000080364:Multifocal Choroiditis; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide